Factors associated with the risk of myocardial infarction in patients with type 2 diabetes mellitus
Keywords:
Risk factors; Myocardial infarction; Type 2 diabetes mellitusAbstract
Myocardial infarction is more frequent and has a worse prognosis in people with type 2 diabetes mellitus than in the general population. In order to identify factors associated with the risk of myocardial infarction in patients with type 2 diabetes mellitus, a case-control analytical study was conducted in 234 patients treated at the Endocrinology and Cardiology services of the Carlos Manuel de Céspedes hospital in the province of Granma, from January 1, 2018 to December 31, 2022. Classical and non-classical cardiovascular risk factors were evaluated, as well as some diabetes-specific conditions. Statistical tests: Chi-square and Student's t-test. Multivariate analysis showed five factors with independent influence on the development of myocardial infarction: microalbuminuria (OR= 21.09, CI= 3.0-148.0, p = 0.002); arterial hypertension (OR= 7.40, CI= 1.4-37.5, p = 0.016); age ≥ 60 years (OR= 6.72, CI= 1.0-44.9, p = 0.049); diabetes duration ≥10 years (OR= 4.07, CI=1.3-11.8, p = 0.010); and low HDL cholesterol (OR= 3.21, CI=1.01-10.1, p = 0.046). The Hosmer-Lemeshow test demonstrated that the data fit the model (p = 0.914). A model was obtained demonstrating the independent influence of microalbuminuria, arterial hypertension, age, diabetes duration, and decreased HDL cholesterol on the development of myocardial infarction in people with type 2 diabetes mellitus.
Downloads
References
1. Palermi A, Saraullo S, MB Giordano, Ricci F, Gallina S, G Renda. Revisiting type 2 myocardial infarction: Unmet clinical needs. Current Problems in Cardiology 50 [Internet]. 2025[citado 31/03/2026]; 2025: 103148. Disponible en: https://doi.org/10.1016/j.cpcardiol.2025.103148
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med [Internet]. 1998 [citado 31/03/2026]; 339(4):229-34. Disponible en: https://www.nejm.org/doi/10.1056/NEJM199807233390404?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
3. Milazzo V, Cosentino N, Genovese S, Campodonico J, Mazza M, De Metrio M, et al. Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. Adv Exp Med Biol [Internet]. 2021 [citado 31/03/2026]; 1307:153-69. Disponible en: https://link.springer.com/chapter/10.1007/5584_2020_481
4. Baviera M, Genovese S, Colacioppo P, Cosentino N, Foresta A, Tettamanti M, et al. Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol [Internet]. 2022 [citado 31/03/2026]; 21(1):223. https://pmc.ncbi.nlm.nih.gov/articles/PMC9618227/pdf/12933_2022_Article_1655.pdf
5. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care [Internet]. 2024 [citado 31/03/2026]; 47(Suppl 1): S179-S218. https://doi.org/10.2337/dc24-S010
6. Andersson C, Nayor M, Tsao CW, Levy D, Vasan RS. Framingham Heart Study: JACC Focus Seminar, 1/8. J Am Coll Cardiol [Internet]. 2021 [citado 31/03/2026]; 77(21):2680-92. Disponible en: https://www.sciencedirect.com/science/article/pii/S0735109721010962?via%3Dihub
7. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care [Internet]. 2023 [citado 31/03/2026]. 46(Suppl 1):S19-S40. Disponible en: https://diabetesjournals.org/care/article/46/Supplement_1/S19/148056/2-Classification-and-Diagnosis-of-Diabetes
8. Roberts-Lewis SF, White CM, Ashworth M, Rose MR. The validity of the International Physical Activity Questionnaire (IPAQ) for adults with progressive muscle diseases. Disabil Rehabil [Internet]. 2022 Nov [citado 1/04/2026]; 44(23):7312-20. Disponible en: https://www.tandfonline.com/doi/epdf/10.1080/09638288.2021.1983042?needAccess=true
9. Sánchez R, Coca A, Molina de Salazar DI, Alcocer L, Aristizabal D, Barbosa E, et al. 2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America. J Hypertens [Internet]. 2025 [citado 1/04/2026]; 43(1):1-34. Disponible en: http://DOI:10.1097/HJH.0000000000003899
10. Purnell JQ. What is Obesity? Definition as a Disease, with Implications for Care. Gastroenterol Clin North Am [Internet]. 2023 [citado 1/04/2026]; 52(2):261-75. Disponible en: http://DOI:10.1016/j.gtc.2023.03.001
11. Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol [Internet]. 2018 [citado 1/04/2026]; 17(1):150-63. Disponible en: http://DOI: 10.1186/s12933-018-0787-8
12. Nanayakkara N, Ranasinha S, Gadowski A, Heritier S, Flack JR, Wischer N, et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. J Diabetes Complications [Internet]. 2018 [citado 1/04/2026]; 32(3):279-90. Disponible en: http://DOI: 10.1016/j.jdiacomp.2017.11.009
13. Raja P, Maxwell AP, Brazil DP. The Potential of Albuminuria as a Biomarker of Diabetic Complications. Cardiovasc Drugs Ther [Internet]. 2021 [citado 1/04/2026]; 35(3):455-66. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8105227/pdf/10557_2020_Article_7035.pdf
14. Waijer SW, Xie D, Inzucchi SE, Zinman B, Koitka A, Mattheus M, et al. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc [Internet]. 2020 [citado 1/04/2026]; 9(18): e016976. Disponible en: http://DOI: 10.1161/JAHA.120.016976
15. Jaén Águila F, Roa Chamorro R, Mediavilla García JD. Utilidad de la monitorización ambulatoria de la presión arterial en fenotipos clínicos específicos. [Internet]. España: AlterMédica; 2023. [citado 03/03/2026]. Disponible en: http://www.alter.es/pdfs/LIBRO_HTA.pdf
16. Wang J, Chen Y, Xu W, Lu N, Cao J, Yu S. Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. PLoS One [Internet]. 2019 [citado 1/04/2026]; 14(4):e0215362. Disponible en: http://DOI: 10.1371/journal.pone.0215362
17. Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol [Internet]. 2023 [citado 1/04/2026]; 20(10):685-95. Disponible en: http://DOI:10.1038/s41569-023-00877-z
18. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol [Internet]. 2022 [citado 1/04/2026]; 80(25):2361-71. Disponible en: https://www.sciencedirect.com/science/article/pii/S0735109722073120?via%3Dihub
19. Denimal D, Benanaya S, Monier S, Simoneau I, Pais de Barros JP, Le Goff W, et al. Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities. J Clin Endocrinol Metab [Internet]. 2022 [citado 1/04/2026]; 107(9):e3816-e23. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9387699/
20. Mostaza JM , Pintó X, Armario P, Masana L, Real JT, Valdivielso P, et al. Estándares SEA 2022 para el control global del riesgo cardiovascular SEA 2022 Standards for Global Control of Cardiovascular Risk. Clínica e Investigación en Arteriosclerosis[Internet]. 2022[citado 1/04/2026]; 34(3):130-79. Disponible en: https://www.sciencedirect.com/science/article/pii/S0214916821001571
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Eduardo Rene Valdes Ramos, Alexis Álvarez Aliaga Álvarez Aliaga, Eduardo Valdés Bencosme
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Avisos de derechos de autor propuestos por Creative Commons
1. Política propuesta para revistas que ofrecen acceso abierto
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
